MRGPR X4 Modulators for Bilirubin-Driven Itch and Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is limited understanding of the function of Mas-related G-protein coupled receptors (MRGPRs), particularly MRGPR X4, which are associated with disorders such as chronic itch, inflammation, autoimmunity, skin disorders, and cardiovascular disease, and current treatments are inadequate for conditions like cholestatic pruritus and uremic pruritus.
Innovation Solution
Development of modulators, such as compounds with the structure of Formula (I), that function as inverse agonists or competitive antagonists to MRGPR X4, specifically targeting this receptor to treat conditions mediated by bilirubin, bile acids, and urobilin, thereby addressing autoimmune diseases and chronic itch.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MRGPR X4 is activated by bilirubin and bile acids, then itch sensation and inflammation are mediated, but chronic itch and autoimmune diseases persist
Solution Approach 1:
The patent converts the harmful activation of MRGPR X4 by bilirubin and bile acids into a beneficial therapeutic approach by developing inverse agonists and antagonists that block this activation. The compounds described in Formula (I) and Formula (II) specifically target MRGPR X4 to prevent pathogenic signaling while maintaining physiological function, thereby transforming the disease mechanism into a treatable target.
Solution Approach 2:
The patent employs parameter changes by modifying the pharmacological activity at MRGPR X4 through inverse agonism and antagonism. The compounds alter the receptor's signaling parameters to shift from pro-inflammatory to anti-inflammatory states, effectively changing the biological outcome of bilirubin and bile acid binding without eliminating the binding capability itself.
2Reliability
If MRGPR X4 modulators are developed to block bilirubin and bile acid activation, then chronic itch and autoimmune diseases are treated, but compound complexity increases
Solution Approach 1:
The patent achieves multi-functionality by designing modulators that can block multiple ligands (bilirubin, bile acids, and other MRGPR X4 activators) through a single mechanism of action at the receptor level. The inverse agonists and antagonists described provide broad-spectrum protection against various pathogenic substances that activate MRGPR X4, reducing the need for multiple separate therapeutic agents.
Solution Approach 2:
The patent simplifies the development process by focusing on parameter changes in the pharmacological activity rather than exploring all possible molecular structures. By targeting specific binding pockets and signaling pathways of MRGPR X4, the compounds achieve high efficacy with optimized molecular architectures that balance potency and synthetic feasibility.
3Measurement precision
If selective MRGPR X4 modulators are used, then specificity for itch and inflammation pathways is improved, but off-target effects may increase
Solution Approach 1:
The patent applies local quality by designing modulators with specific structural features that target particular regions of the MRGPR X4 receptor binding pocket. The compounds exhibit selective affinity for the biliverdin/bilirubin binding site, allowing precise modulation of MRGPR X4 signaling while minimizing interactions with other receptor subtypes and biological targets.
Solution Approach 2:
The patent incorporates feedback mechanisms through inverse agonism, where the modulators continuously monitor and counteract pathogenic signaling activity. The inverse agonists provide negative feedback by stabilizing the receptor in an inactive state, preventing downstream pro-inflammatory signaling while allowing physiological functions to proceed normally.
Data Source
AI summary
Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I):or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.